According to the study, medications known as selective serotonin reuptake inhibitors, or SSRIs, are frequently used to treat seasonal affective disorder. There are several branded and generic medications available on the seasonal affective disorder therapeutics market size however, buproban and citalopram continue to sell at a relatively higher rate. FMI credits this dominance to the widely accessible generic versions of the aforementioned medications.
The market for treatments for seasonal affective disorder is anticipated to expand at a 4.3% CAGR. The market is currently valued at US$ 848.2 million, and by the end of 2028, it is anticipated to be worth US$ 1.1 billion.
Bright light therapy that has been the most preferred line of treatment in seasonal affective disorder therapeutics continues to receive strong support from physicians and patients owing to positive end results. While more than half the sales of devices used in seasonal affective disorder therapeutics is accounted by light boxes, sales of desk lamps are also thriving at a brisk rate.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-8821
A highly recommended prophylactic measure involved in seasonal affective disorder therapeutics, light therapy is characterized by its rapid, reliable, and highly anti-depressant action. Extensive adoption of bright light therapy by the patients afflicted by a sub-syndromal disease and self-reporting patient population prompts at bolstered revenue visibility prospected for seasonal affective disorder treatment therapeutics in coming years.
Key Players :
- Allergan plc.,
- Eli Lily Company,
- GlaxoSmithKline plc,
- Pfizer Inc.,
- Teva Pharmaceuticals Inc.,
- Bausch Health Companies Inc.,
- F. Hoffmann-La Roche AG, Mylan N.V.,
- Sanofi AG, Novartis AG,
- Janssen Pharmaceuticals, Inc.,
- The Sunbox Company,
- Verilux, Inc.,
- Carex Health,
- Northern Light Technologies,
- Beurer GmbH and Koninklijke Philips N.V.
Demand for Combination Therapy for SAD Picking Up
The report opines that light therapy is the first line of treatment that seasonal affective disorder therapeutics providers opt for. However, a possible ineffective outcome for certain patients of SAD related psychiatric illnesses and depression creates scope of combination therapies. Some of the recently reported clinical trials emphasize potential efficacy of combination of light therapy, psychotherapy, talk therapy, and antidepressants in seasonal affective disorder therapeutics.
Inaccessibility at workplaces or during traveling has been a shortfall of light box therapy over the years. To help patients suffering from SAD explore non-conventional alternatives to seasonal affective disorder therapeutics, Austria-based med-tech startup, Active Wearables, recently launched a wearable device – Pocket Sky – providing light therapy, practically anywhere. The wearable has a wireless charging feature and the battery life is claimed to last for a couple of weeks. The Pocket Sky will potentially serve as a portable and lightweight light therapy solution to patients of seasonal affective disorder. Such innovations will continue to innovate the seasonal affective disorder therapeutics market landscape.
Inadequate availability of research data and ineffective documentation, especially related to use of bright light and blue light in light therapy, is posing a long-term challenge to rapid revenue growth of seasonal affective disorder therapeutics market. Moreover, proven adversities associated with excessive use of antidepressants also remain a concern among physicians and patients alike, limiting healthy growth prospects of seasonal affective disorder therapeutics market.
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/askus/rep-gb-8821
The report tracks performance of global seasonal affective therapeutics market over 2018-2028. In-depth strategic profiles of some of the leading players have been covered in the report, including Allergan plc, Eli Lily Company, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Sanofi AG, Novartis AG, Janssen Pharmaceuticals, Inc., and Koninklijke Philips N.V. among others.
Key Segments:
Seasonal Affective Disorder Therapeutics Market by Treatment Type:
- Seasonal Affective Disorder Therapeutic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
- Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Seasonal Affective Disorder Therapeutic Devices
- Light Boxes
- Dawn Stimulators
- Desk Lamps
- Sun Visors
Seasonal Affective Disorder Therapeutics Market by Disorder Type:
- Seasonal Affective Disorder Therapeutics for Unipolar Disorders
- Fall-Winter Onset
- Spring-Summer Onset
- Seasonal Affective Disorder Therapeutics for Bipolar Disorders
Seasonal Affective Disorder Therapeutics Market by Distribution Channel:
- Institutional Sales
- Seasonal Affective Disorder Therapeutics for Hospitals
- Seasonal Affective Disorder Therapeutics for Clinics
- Seasonal Affective Disorder Therapeutics for Wellness Centres & Spas
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Online Sales
Seasonal Affective Disorder Therapeutics Market by Region:
- North America Seasonal Affective Disorder Therapeutics Market
- Latin America Seasonal Affective Disorder Therapeutics Market
- Europe Seasonal Affective Disorder Therapeutics Market
- East Asia Seasonal Affective Disorder Therapeutics Market
- South Asia & Pacific Seasonal Affective Disorder Therapeutics Market
- Middle East & Africa (MEA) Seasonal Affective Disorder Therapeutics Market
Unlock Tailored Insights: Customize Your Report for Maximum Impact :
https://www.futuremarketinsights.com/customization-available/rep-gb-8821
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
